




PHARMACEUTICAL 2023

Foghorn Therapeutics Inc.
Rank 325 of 446





PHARMACEUTICAL 2023

Foghorn Therapeutics Inc.
Rank 325 of 446



The relative strengths and weaknesses of Foghorn Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foghorn Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Foghorn Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 198% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 70% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	351,399
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55,205
Liabilities, Non-Current	349,566
Other Assets	53,484
Other Compr. Net Income	-3,976
Other Expenses	0
Other Liabilities	0
Other Net Income	8,255
Other Revenues	19,228
Property and Equipment	0
Research and Development	105,618
Selling, General and Administrative Expense	30,747

Output Variable	Value in 1000 USD
Assets	404,883
Liabilities	404,771
Expenses	136,365
Revenues	19,228
Stockholders Equity	112
Net Income	-108,882
Comprehensive Net Income	-110,870
Economic Capital Ratio	-27%